William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
16290
portfolio_page-template-default,single,single-portfolio_page,postid-16290,bridge-core-2.5.8,ajax_fade,page_not_loaded,,qode-theme-ver-24.3,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.2,vc_responsive

William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.

Category
Latests Media
About This Project